Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.
Muhammad AjmalJacob FriedmanQurat Ul Ain Riaz SipraTom LassarPublished in: Cardiovascular therapeutics (2021)
Direct oral anticoagulants (DOACs) are widely used for the prevention of stroke in nonvalvular atrial fibrillation, treatment of deep venous thrombosis and pulmonary embolism, and as prophylaxis after hip and knee surgery after approval by the Food and Drug Administration. In the last decade, DOACs were studied for various indications; this review is focused on rivaroxaban, a factor Xa inhibitor, which is used in an expanded evidence-based fashion for coronary artery disease, peripheral artery disease, heart failure, malignancy, and prophylaxis of deep venous thrombosis in acute medical illnesses.
Keyphrases
- direct oral anticoagulants
- atrial fibrillation
- pulmonary embolism
- drug administration
- heart failure
- peripheral artery disease
- cardiovascular disease
- coronary artery disease
- venous thromboembolism
- oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- inferior vena cava
- percutaneous coronary intervention
- minimally invasive
- liver failure
- coronary artery bypass
- healthcare
- case report
- cardiovascular events
- respiratory failure
- type diabetes
- metabolic syndrome
- left ventricular
- drug induced
- combination therapy
- intensive care unit
- acute coronary syndrome
- aortic dissection
- mitral valve
- climate change
- acute heart failure